2026/04/30 by Qianqian Cui, Yunxiao Li, Shuangqi Gao +2
Biochemistry, Genetics and Molecular Biology · Neuroscience · #Action (physics) #Adenosine and Purinergic Signaling #Extracellular #Function (biology) #Phosphodiesterase function and regulation #Purine #Purinergic receptor #Purinergic signalling #Signal transduction #Tryptophan and brain disorders
paper · doi:10.1080/00207454.2026.2666245
openalex publication_date 2026/04/30 · crossref created 2026/04/30 · openalex created_date 2026/05/02 · crossref issued 2026/05/08 · crossref published 2026/05/08 · crossref published-online 2026/05/08 · crossref deposited 2026/07/30 · crossref indexed 2026/07/30 · openalex updated_date 2026/08/01 · crossref published-print 2026/08/03
Major depressive disorder, as a common neuropsychiatric disorder, has a complex pathogenesis that has not yet been fully elucidated, posing significant challenges to clinical treatment. In recent years, the role of the purinergic signaling system in the pathophysiological processes of depression has garnered increasing attention. The purinergic signaling primarily involves extracellular purine compounds such as ATP and adenosine, which act as transmitters by binding to their corresponding purine receptors (P1 and P2). Purinergic signaling can participate in depression by affecting the function of astrocytes, neuronal plasticity, and the activity of microglia. This paper systematically reviews the latest research advancements in purinergic signaling related to depression by searching for articles on the PubMed using the keywords 'purinergic' OR 'ATP' OR 'adenosine' and 'depression'. It focuses on the molecular mechanisms of action and discusses the limitations and controversial issues present in current research, aiming to provide new theoretical foundations and treatment strategies for the precise treatment of depression.